Publications by authors named "Po-Lan Su"

Article Synopsis
  • This study examines the safety and survival outcomes of osimertinib compared to other EGFR TKIs, specifically looking at the incidence of cancer therapy-related cardiac events (CTRCEs) among patients with EGFR-mutant non-small cell lung cancer in Taiwan.
  • Conducted over a median follow-up of 23.2 months with 401 patients, the study assessed various heart-related issues like arrhythmias and heart failure while controlling for multiple factors such as age and existing health conditions.
  • Results from the analysis, which utilized complex statistical models to address potential confounding variables, aim to clarify the relationship between using osimertinib and the risk of CTRCEs, including its impact on overall survival.
View Article and Find Full Text PDF
Article Synopsis
  • * Various therapies targeting DLL3 include antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR T-cell therapies, with tarlatamab showing promising results and currently under FDA review.
  • * Ongoing clinical trials are set to assess the effectiveness of DLL3-targeted therapies, including novel T-cell engagers and radiotherapy, emphasizing the need for further research to improve treatment outcomes for SCLC patients.
View Article and Find Full Text PDF

Tracheopathia osteochondroplastica (TO) is a rare and benign condition. It typically manifests as multiple osteocartilaginous nodules in the submucosa of the central airway. TO-related clinical symptoms and physical signs are nonspecific.

View Article and Find Full Text PDF

Background: Oligoprogression is an emerging issue in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, the surgical treatment for central nervous system (CNS) oligoprogression is not widely discussed. We investigated the outcomes of craniotomy with adjuvant whole-brain radiotherapy (WBRT) and subsequent therapies for CNS oligoprogression in patients with EGFR-mutated NSCLC.

View Article and Find Full Text PDF
Article Synopsis
  • EGFR-TKIs are standard treatments for patients with EGFR-mutant non-small cell lung cancer (NSCLC), but their effectiveness can be impacted by other mutations, making treatment outcomes highly variable.
  • A cost-effective nomogram was developed using pre-treatment clinical characteristics to help stratify patients based on their risk of disease progression, avoiding the high costs of comprehensive genetic testing.
  • The study involved analyzing data from 761 patients and identified seven key prognostic factors to classify them into three risk groups, offering a more tailored approach to determine optimal treatment strategies for EGFR-mutant NSCLC patients.
View Article and Find Full Text PDF

Background: Invasive pulmonary aspergillosis (IPA) can negatively impact cancer patients' survival. It remains uncertain whether IPA's impact on patient outcomes varies by treatment approach in advanced lung cancer.

Objectives: To explore the association between IPA and outcomes in patients with advanced lung cancer receiving different treatments.

View Article and Find Full Text PDF

Doping sorted graphene quantum dots (GQDs) with heteroatoms and functionalizing them with amino acid could improve their radiative recombination and two-photon properties-including their excitation-wavelength-independent photoluminescence from the ultraviolet to the near-infrared-I (NIR-I) region, absorption, quantum yield, absolute cross section, lifetime, and radiative-to-nonradiative decay ratio-under two-photon excitation (TPE) at a low excitation energy and short photoexcitation duration, as determined using a self-made optical microscopy system with a femtosecond Ti-sapphire laser. Four types of sorted GQDs were investigated: undoped GQDs, nitrogen-doped GQDs (N-GQDs), amino-functionalized GQDs (amino-GQDs), and N-doped and amino-functionalized GQDs (amino-N-GQDs). Among them, the sorted amino-N-GQDs are effective as a two-photon photosensitizer and generate the highest quantity of reactive oxygen species for the elimination of multidrug-resistant cancer cells through two-photon photodynamic therapy (PDT).

View Article and Find Full Text PDF

Although combination therapy including chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) of patients with non-small-cell lung cancer (NSCLC), there is a higher incidence of adverse events and treatment discontinuation. Since programmed death-ligand 1 (PD-L1) could not serve as a predictive biomarker, we investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictive biomarker. In our previous research, we demonstrated that a low NLR could predict survival benefits when patients with high PD-L1 expression (> 50%) received chemoimmunotherapy as opposed to immunotherapy alone.

View Article and Find Full Text PDF

Real-world data regarding the T790M mutation rate after acquiring resistance to first-line combination therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and bevacizumab in patients with advanced non-small-cell lung cancer (NSCLC) are limited. The present study was aimed at analyzing predictors of acquired T790M mutations in this patient group. A total of 107 patients who received first-line combination therapy with EGFR-TKIs and bevacizumab at 11 tertiary referral centers in Taiwan were enrolled in this multicenter retrospective study.

View Article and Find Full Text PDF

Alveolar macrophages (AMs) are the drivers of pulmonary cytokine storm in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to investigate clinical-regulatory factors for the entrance protein of SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) in AMs. Human AMs were collected from 56 patients using bronchoalveolar lavage.

View Article and Find Full Text PDF

Background: Some prospective studies have shown that second-generation tyrosine kinase inhibitors (TKIs) provide better control in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations. However, studies comparing second-line chemotherapy efficacy between NSCLC patients with common and uncommon EGFR mutations remain rare. This retrospective study compared treatment outcomes in these patients.

View Article and Find Full Text PDF
Article Synopsis
  • PD-L1 expression's ability to predict the effectiveness of EGFR-TKIs in NSCLC is debated, with recent studies suggesting various pathways can influence its signaling.
  • Researchers investigated how mechanisms like STAT3, AKT, and BIM expression impact PD-L1's prognostic significance in EGFR mutant advanced NSCLC patients who received treatment.
  • Results showed that high BIM expression correlated with shorter progression-free survival, indicating that BIM may be a crucial factor in determining the response to EGFR-TKIs like gefitinib, highlighting a need for further studies to confirm these findings.
View Article and Find Full Text PDF

Tumor resection could increase treatment efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). This study aimed to retrospectively analyze patients with advanced EGFR-mutant NSCLC from a Taiwanese tertiary center and receiving EGFR-TKI treatment with or without tumor resection. A total of 349 patients were enrolled.

View Article and Find Full Text PDF

Acute respiratory distress syndrome (ARDS) is characterized by acute-onset rapid-deteriorating inflammatory lung injury. Although the preservation of spontaneous breathing may have physiological benefits in oxygenation, increasing evidence shows that vigorous spontaneous breathing may aggravate lung injury (i.e.

View Article and Find Full Text PDF

The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy or radiotherapy in programmed death-ligand 1 high expressors remain limited. This study aimed to retrospectively compare the treatment efficacy of the therapies by studying 47 patients with treatment-naïve advanced NSCLC who received ICI monotherapy ( = 28) or combination therapy either with chemotherapy or radiotherapy ( = 19).

View Article and Find Full Text PDF

Telisotuzumab vedotin is a -targeting antibody-drug conjugate that has demonstrated a good treatment response in patients with wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been standardized. Here, we present a case of a 56-year-old woman diagnosed with fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin.

View Article and Find Full Text PDF

Background: Electrical impedance tomography (EIT) can be used for continuous monitoring of pulmonary ventilation. However, no proper method has been developed for the separation of pulmonary ventilation and perfusion signals and the measurement of the associated ventilation/ perfusion (V/Q) ratio. Previously, various methods have been used to extract these components; however, these have not been able to effectively separate and validate cardiac- and pulmonary- related images.

View Article and Find Full Text PDF

fusions are rare driver oncogenes in non-small cell lung cancer (NSCLC). Similar with V600E mutation, it could also activate the MAPK signaling pathway. There are a few case reports which had indicated the potential response to BRAF inhibitors and its important role as driver mutation.

View Article and Find Full Text PDF

Objective: To determine whether combined transoral robotic surgery and postoperative oropharyngeal rehabilitation are effective for reducing the severity of obstructive sleep apnea.

Study Design: A quasi-experimental study enrolled participants without blinding between May 2019 and April 2021.

Setting: Single-center study at National Cheng Kung University Hospital.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on treatment strategies for patients with stage III non-small cell lung cancer (NSCLC), particularly those with N2-positive and unresectable types.
  • It analyzes data from the KINDLE study, a large observational study, highlighting the progression-free survival (PFS) and overall survival (OS) of various treatment approaches.
  • Results indicate that surgery may improve outcomes for N2-positive patients, while upfront chemoradiotherapy combined with sequential EGFR-TKI is suggested for unresectable -mutant NSCLC, with a call for further randomized studies to confirm these findings.*
View Article and Find Full Text PDF

Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC). This study aimed to assess whether the presence of targetable driver mutations affects the efficacy of the combination of immunotherapy and chemotherapy. We enrolled patients with early-stage operable NSCLC who received preoperative neoadjuvant therapy between January 1, 2017, and December 30, 2020.

View Article and Find Full Text PDF

This study delineated the characteristics of 24 (11.2%) culture-positive, influenza-associated pulmonary aspergillosis (IAPA) patients out of 215 patients with severe influenza during 2016-2019 in a medical center in southern Taiwan. Twenty (83.

View Article and Find Full Text PDF

Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor (EGFR)-mutant advanced-stage non-small cell lung cancer (NSCLC). However, TKIs can cause some severe adverse events, which are more prevalent within first-generation EGFR-TKI use than with second-generation inhibitors. Herein, we report a case of a patient with advanced-stage EGFR-mutant NSCLC who developed drug reaction with eosinophilia and systemic symptoms (DRESS) after receiving treatment with afatinib.

View Article and Find Full Text PDF